Korean Circulation Journal最新文献_第4页

Current Therapeutic Patterns of Pulmonary Arterial Hypertension in Korea: A Five-Year Follow-up of the PHOENIKS Longitudinal Cohort. 目前韩国肺动脉高压的治疗模式：对PHOENIKS纵向队列的5年随访。

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-08-01 DOI: 10.4070/kcj.2025.0001

Kyung Eun Ha, Seho Park, Wook-Jin Chung, Gee-Hee Kim, Jae-Hyeong Park, Jung Hyun Choi, Hyungseop Kim, Ran Heo, Dae Hwan Bae, Youngwoo Jang

{"title":"Current Therapeutic Patterns of Pulmonary Arterial Hypertension in Korea: A Five-Year Follow-up of the PHOENIKS Longitudinal Cohort.","authors":"Kyung Eun Ha, Seho Park, Wook-Jin Chung, Gee-Hee Kim, Jae-Hyeong Park, Jung Hyun Choi, Hyungseop Kim, Ran Heo, Dae Hwan Bae, Youngwoo Jang","doi":"10.4070/kcj.2025.0001","DOIUrl":"https://doi.org/10.4070/kcj.2025.0001","url":null,"abstract":"Background and objectives: The 2022 revised pulmonary hypertension guidelines emphasize risk stratification to enhance outcomes, necessitating investigation into adherence. This study aimed to examine the treatment patterns of patients in the Pulmonary Arterial Hypertension (PAH) Platform for deep Phenotyping in Korean Subjects (PHOENIKS) study cohort.Methods: A total of 321 patients from the PHOENIKS cohort were included, consisting of 101 patients in phase 1 (2018-2020) and 220 in phase 2 (2021-2023). A total of 275 patients with either idiopathic PAH or associated PAH were included in the final analysis. Risk assessment was conducted utilizing an online calculator that integrates multiple validated risk stratification models. Adherence to the revised guidelines was evaluated, and survival outcomes were analyzed over the study period.Results: The cohort consisted primarily of middle-aged and female patients (mean age 51.96±15 years, 71% female). A total of 53% had idiopathic PAH and 47% had associated PAH. Intermediate-risk patients comprised 62% of the cohort during the initial diagnosis. The proportion of low-risk patients increased from 34% to 64% throughout the follow-up period. Adherence to the revised guidelines slightly improved during the study period, though only 26% of patients demonstrated compliance. The one-year survival rate was 96%, whereas the 3-year survival rate was 87%.Conclusions: The current Korean PAH treatment strategy must be improved to align with the revised guidelines and optimize patient outcomes. Further efforts are needed to change health insurance coverage criteria to enhance guideline adherence.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic Value of Plasma Big Endothelin-1 in Patients Hospitalized for Heart Failure. 血浆大内皮素-1在心力衰竭住院患者中的预后价值。

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-08-01 Epub Date: 2025-04-11 DOI: 10.4070/kcj.2024.0354

Jinxi Wang, Jiayu Feng, Gary Tse, Mei Zhai, Yan Huang, Qiong Zhou, Xiaofeng Zhuang, Huihui Liu, Yuhui Zhang, Jian Zhang

{"title":"Prognostic Value of Plasma Big Endothelin-1 in Patients Hospitalized for Heart Failure.","authors":"Jinxi Wang, Jiayu Feng, Gary Tse, Mei Zhai, Yan Huang, Qiong Zhou, Xiaofeng Zhuang, Huihui Liu, Yuhui Zhang, Jian Zhang","doi":"10.4070/kcj.2024.0354","DOIUrl":"10.4070/kcj.2024.0354","url":null,"abstract":"Background and objectives: Endothelin-1 (ET-1) is a potent vasoconstrictor and multifunctional neuroendocrine hormone that is closely associated with the pathophysiology of heart failure (HF). Currently, the evidence about the predictive value of big ET-1 in HF remains insufficient. This study aims to investigate the prognostic importance of big ET-1 in HF.Methods: We examined the incidence of cardiovascular death in a single-center retrospective cohort of HF (de novo, worsening, or chronic included).Results: The 4,368 hospitalized HF patients were enrolled. During the median follow-up of 875 (365-1,400) days, 851 (19.5%) patients had primary outcome events. Big ET-1 was independently associated with cardiovascular death as a continuous variable (hazard ratio [HR], 1.13; 95% confidence interval [CI], 1.06-1.21; p<0.001) and by tertiles (HR, 1.35; 95% CI, 1.06-1.72; p=0.017 for tertile 2 and HR, 1.70; 95% CI, 1.32-2.19; p<0.001 for tertile 3). This pattern of risk was maintained after further adjustment for NT-proBNP (HR, 1.11; 95% CI, 1.03-1.19; p=0.006 for continuous variable, HR, 1.30; 95% CI, 1.02-1.67; p=0.035 for tertile 2, and HR, 1.69; 95% CI, 1.23-2.05; p=0.034 for tertile 3). Net reclassification index (NRI) and integrated discrimination improvement (IDI) analysis showed that big ET-1 provided additional predictive power in combination with NT-proBNP (NRI, 0.11; 95% CI, 0.04-0.17; p=0.012 and IDI, 0.012; 95% CI, 0.003-0.017; p<0.001).Conclusions: Elevated big ET-1 was independently associated with cardiovascular death in patients with HF. Big ET-1 may be a promising indicator of HF prognosis. In combination with NT-proBNP, big ET-1 may provide incremental predictive information.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":"705-717"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulsta Valve, Unique Self-Expandable Transcatheter Pulmonary Valve. Pulsta阀，独特的自膨胀经导管肺阀。

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-08-01 Epub Date: 2025-04-22 DOI: 10.4070/kcj.2025.0083

Gi Beom Kim

{"title":"Pulsta Valve, Unique Self-Expandable Transcatheter Pulmonary Valve.","authors":"Gi Beom Kim","doi":"10.4070/kcj.2025.0083","DOIUrl":"10.4070/kcj.2025.0083","url":null,"abstract":"Large sized valve of a self-expandable nature has been suggested as the next generation transcatheter pulmonary valve to implant for various type of native right ventricular outflow tract (RVOT) lesions. Tissue engineered Pulsta valve including decellularization, alpha-galactosidase treatment provide longer valve durability and knitted woven nitinol wire stent provide low risk of stent fracture at the dynamic RVOT. Compact tubular design of Pulsta valve also offer easy valve loading to delivery system and good trackability to valve landing area. From the worldwide experience over 750 cases by February 2025, adaptability of Pulsta valve for various RVOT has proven. Pulsta valve has been implanted for various type of main pulmonary artery (PA) including pyramidal, reverse pyramidal shape and for branch PA stenosis including stent in the branch PA. In case of extremely large native RVOT anatomy, Pulsta valve can be implanted in both branch PA respectively. For the stenotic RVOT or failed bioprosthetic valve, Pulsta valve can also be implanted with or without pre-stenting. Recapturability using delivery system itself if less than one third of valve were flared outside of sheath and capability of whole delivery system retrieval using hooking system are another merit for safe procedure. Though the experience of Pulsta valve for various RVOT diseases is newly accumulated in many centers every day, we still have to learn more about Pulsta valve applicability for various RVOT diseases and long-term outcomes after Pulsta valve implantation.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":"659-671"},"PeriodicalIF":3.1,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rotational Atherectomy Outcomes Across Operator Experience: Can Less Experience Still Deliver Safe and Effective Outcomes? 不同手术经验的旋转动脉粥样硬化切除术结果：经验较少是否仍然可以提供安全有效的结果？

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-08-01 DOI: 10.4070/kcj.2025.0183

Jin Jung, Sung-Ho Her

引用次数: 0

Beyond Biventricular Pacing: Revisiting CRT Strategies in the Asian Heart Failure Population. 超越双心室起搏：重新审视亚洲心力衰竭人群的CRT策略。

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-08-01 Epub Date: 2025-05-08 DOI: 10.4070/kcj.2025.0129

Min Kim

引用次数: 0

Real-World Value of Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) in Korea: Moving From Cost-Effectiveness to Implementation. 血管紧张素受体- neprilysin抑制剂（ARNIs）在韩国的实际价值：从成本效益到实施。

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-07-28 DOI: 10.4070/kcj.2025.0215

Tae Hyun Kim

引用次数: 0

Expanding Global DES Horizons With the Korean-Made CENTUM™ Stent. 韩国CENTUM支架拓展全球DES视野

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-07-25 DOI: 10.4070/kcj.2025.0270

Jung-Joon Cha, Soon Jun Hong

引用次数: 0

High Plasma Renin and Aldosterone Levels Are Associated With a Unique Phenotype in Primary Hypertension. 高血浆肾素和醛固酮水平与原发性高血压的独特表型相关。

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-07-24 DOI: 10.4070/kcj.2025.0140

Jung Sun Cho, Ji-Hoon Jung, Woojin Kwon, Woo-Baek Chung, Sang Hyun Ihm

{"title":"High Plasma Renin and Aldosterone Levels Are Associated With a Unique Phenotype in Primary Hypertension.","authors":"Jung Sun Cho, Ji-Hoon Jung, Woojin Kwon, Woo-Baek Chung, Sang Hyun Ihm","doi":"10.4070/kcj.2025.0140","DOIUrl":"https://doi.org/10.4070/kcj.2025.0140","url":null,"abstract":"Background and objectives: Substantial efforts have been made to categorize the diverse and broad population of individuals with primary hypertension into more defined, homogeneous subgroups according to their hormonal responses to biological stimuli, such as low-renin hypertension. This study aimed to explore the phenotype and prognosis of patients with untreated primary hypertension with high renin and aldosterone levels.Methods: In this study, we explored hypertensive phenotypes related to renin and aldosterone levels in untreated patients with primary hypertension (n=747). Patients were stratified into 4 groups on the basis of plasma renin activity (≥1.0 ng/mL/hr or <1.0 ng/mL/hr) and the plasma aldosterone concentration (≥15 ng/dL or <15 ng/dL).: high renin and aldosterone (n=172), low renin and high aldosterone (n=70), high renin and low aldosterone (n=308), and low renin and aldosterone (n=196).Results: Multinomial logistic regression analysis revealed that younger age (p<0.001), higher pulse rates (p=0.002), and greater nighttime systolic blood pressure (p=0.046) were independent predictors of high renin and aldosterone levels. Microalbuminuria (25.5%, p<0.001) and elevated uric acid levels (5.5±1.4 mg/dL, p=0.006) were also more prevalent in this group.Conclusions: These findings highlight the importance of stratifying hypertensive phenotypes to enable personalized treatment for primary hypertensives with elevated renin and aldosterone levels.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anatomical Snuffbox Versus Dorsum of the Hand for Optimal Access Site in Distal Radial Access: Insight From the KODRA Registry. 解剖鼻烟壶与手背在远端桡骨通路中的最佳通路位置：来自KODRA注册表的见解。

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-07-21 DOI: 10.4070/kcj.2025.0107

Sung Woo Cho, Jun-Won Lee, Tae-Hyun Yang, Jeong-Sook Seo, Yongcheol Kim, Bong-Ki Lee, Sang-Yong Yoo, Sang Yeub Lee, Chan Joon Kim, Jin Sup Park, Jung Ho Heo, Do Hoi Kim, Jin Bae Lee, Dong-Kie Kim, Jino Park, Jun Ho Bae, Sung-Yun Lee, Seung-Hwan Lee, Han-Young Jin

{"title":"Anatomical Snuffbox Versus Dorsum of the Hand for Optimal Access Site in Distal Radial Access: Insight From the KODRA Registry.","authors":"Sung Woo Cho, Jun-Won Lee, Tae-Hyun Yang, Jeong-Sook Seo, Yongcheol Kim, Bong-Ki Lee, Sang-Yong Yoo, Sang Yeub Lee, Chan Joon Kim, Jin Sup Park, Jung Ho Heo, Do Hoi Kim, Jin Bae Lee, Dong-Kie Kim, Jino Park, Jun Ho Bae, Sung-Yun Lee, Seung-Hwan Lee, Han-Young Jin","doi":"10.4070/kcj.2025.0107","DOIUrl":"https://doi.org/10.4070/kcj.2025.0107","url":null,"abstract":"Background and objectives: Distal radial access (DRA) has been recognized as an alternative to conventional radial access, with potential puncture sites at the anatomical snuffbox and on the dorsum of the hand. However, the optimal puncture site remains unknown. This study aims to evaluate the efficacy and safety of DRA at these two sites.Methods: This analysis was performed using the KODRA (Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach) registry. The primary efficacy endpoint was defined as successful puncture and completion of the coronary procedure without access-site crossover, while the primary safety endpoint was the DRA-related bleeding.Results: A total of 4,977 and 4,644 patients were included in efficacy and safety analyses, respectively. DRA via the anatomical snuffbox improved the primary efficacy endpoint (odds ratio [OR], 2.358; 95% confidence interval [CI], 1.800-3.090; p<0.001), but did not differ from the dorsum of the hand approach in the primary safety endpoint (OR, 1.305; 95% CI, 0.792-2.150; p=0.296). The anatomical snuffbox approach was also associated with higher puncture success rates (OR, 2.244; 95% CI, 1.672-3.010; p<0.001), but with an increased rate of prolonged hemostasis >180 minutes (OR, 15.002; 95% CI, 7.708-29.197; p<0.001).Conclusions: Compared to the dorsum of the hand approach, DRA via the anatomical snuffbox demonstrated higher procedural efficacy, but was associated with prolonged hemostasis, without an increase in DRA-related bleeding. Further research is needed to determine the optimal site for DRA.","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Short-term and Standard Duration Dual Antiplatelet Therapy in Elderly Patients: A Pooled Analysis of Five Korean Randomized Clinical Trials. 老年患者短期和标准时间双重抗血小板治疗的比较：五项韩国随机临床试验的汇总分析。

IF 3.1 3区医学

Korean Circulation Journal Pub Date : 2025-07-14 DOI: 10.4070/kcj.2025.0093

In Tae Jin, Yongcheol Kim, Seok-Jae Heo, Yong-Joon Lee, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Deok-Kyu Cho, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Byeong-Keuk Kim

{"title":"Comparison of Short-term and Standard Duration Dual Antiplatelet Therapy in Elderly Patients: A Pooled Analysis of Five Korean Randomized Clinical Trials.","authors":"In Tae Jin, Yongcheol Kim, Seok-Jae Heo, Yong-Joon Lee, Seung-Jun Lee, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, Deok-Kyu Cho, Young-Guk Ko, Donghoon Choi, Myeong-Ki Hong, Byeong-Keuk Kim","doi":"10.4070/kcj.2025.0093","DOIUrl":"https://doi.org/10.4070/kcj.2025.0093","url":null,"abstract":"Backgrounds and objectives: Data on the optimal duration of dual antiplatelet therapy (DAPT) by age in patients undergoing percutaneous coronary intervention (PCI) are limited. This study assessed clinical outcomes based on age groups and DAPT duration, focusing on patients aged ≥75 years.Methods: We analyzed data from 10,487 patients across 5 Korean randomized trials examining the impact of DAPT durations on clinical outcomes after drug-eluting stent implantation. Patients were categorized into 2 groups: ≥75 years (n=1,571) and <75 years (n=8,916). Each group was further stratified into short-term DAPT (1-6 months) and standard DAPT (12 months). The primary outcome was major bleeding within 12 months of PCI. Major adverse cardiovascular and cerebrovascular events (MACCE) and net adverse clinical events (NACE), a composite of MACCE and major bleeding, were also compared.Results: Patients aged ≥75 had a higher risk of major bleeding and MACCE than those aged <75. In patients aged ≥75, standard DAPT was associated with a higher risk of major bleeding than short-term DAPT (hazard ratio [HR], 2.34; 95% confidence interval [CI], 1.17-4.68; p=0.016). In patients aged <75 years, the risk was comparable (HR, 1.45; 95% CI, 1.00-2.10; p=0.053), with no significant interaction between groups (p=0.207). The risks of MACCE and NACE did not differ significantly between DAPT strategies or age groups.Conclusions: Standard DAPT strategy may increase bleeding risk in elderly patients without reducing ischemic events, despite no significant age-treatment interaction.Trial registration: ClinicalTrials.gov Identifier: NCT01145079 (RESET), NCT01308281 (IVUS-XPL), NCT01752894 (DETECT-OCT), NCT02494895 (TICO), NCT02513810 (One-Month-DAPT).","PeriodicalId":17850,"journal":{"name":"Korean Circulation Journal","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0